keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis C guidelines

keyword
https://www.readbyqxmd.com/read/29672896/hepatitis-c-in-patients-with-renal-disease-a-deeper-dive-into-the-kdigo-guideline
#1
Norah A Terrault
No abstract text is available yet for this article.
April 19, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29667379/lymphogranuloma-venereum-genovar-l2b-concomitantly-with-syphilis-and-hepatitis-c-in-a-male-patient-in-poland-%C3%A2-case-report
#2
Agnieszka Beata Serwin, Marta Koper, Magnus Unemo
We describe the first case of lymphogranuloma venereum (LGV) in Poland, with inguino-femoral lymphadenopathy, diagnosed and successfully treated according to the 2013 European LGV guideline. Chlamydia trachomatis genovar L2b, mainly responsible for the ongoing LGV epidemics among men who have sex with men (MSM) in Western European countries, was confirmed. The case also verified that co-infections with other sexually transmitted infections (syphilis and hepatitis C virus) are frequent in MSM LGV patients, as well as the very large difficulties with contact tracing for these patients...
2018: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/29663585/perioperative-anticoagulation-practices-for-pediatric-liver-transplantation
#3
Stylianos Voulgarelis, Bernadette Vitola, Stacee M Lerret, Johnny C Hong, John P Scott
Despite continued advancements in perioperative care for pediatric liver transplant (LT), graft-threatening vascular occlusion events including hepatic artery thrombosis (HAT) and portal vein thrombosis (PVT) remain a source of significant morbidity and mortality. Perioperative anticoagulation is commonly used for the prevention of HAT and PVT, but evidence-based guidelines are lacking. The goals of this survey were to determine the frequency of use of an anticoagulation protocol and to describe variation in anticoagulation practices among pediatric LT centers...
April 16, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29659605/chronic-kidney-disease-in-the-global-adult-hiv-infected-population-a-systematic-review-and-meta-analysis
#4
Udeme E Ekrikpo, Andre P Kengne, Aminu K Bello, Emmanuel E Effa, Jean Jacques Noubiap, Babatunde L Salako, Brian L Rayner, Giuseppe Remuzzi, Ikechi G Okpechi
INTRODUCTION: The widespread use of antiretroviral therapies (ART) has increased life expectancy in HIV patients, predisposing them to chronic non-communicable diseases including Chronic Kidney Disease (CKD). We performed a systematic review and meta-analysis (PROSPERO registration number CRD42016036246) to determine the global and regional prevalence of CKD in HIV patients. METHODS: We searched PubMed, Web of Science, EBSCO and AJOL for articles published between January 1982 and May 2016...
2018: PloS One
https://www.readbyqxmd.com/read/29628202/health-status-of-afro-asian-refugees-in-an-italian-urban-area-a-cross-sectional-monocentric-study
#5
R Del Pinto, D Pietropaoli, U Russomando, P Evangelista, C Ferri
OBJECTIVES: The recent sociopolitical events in the Mediterranean and Middle Eastern areas have significantly impacted international migration flows. As disease prevalence and type are different among western and Afro-Asian countries, physicians dealing with refugees should be aware of their specific health needs. We aimed at evaluating the health status and disease history of refugees at their arrival in the urban area of L'Aquila (Italy). STUDY DESIGN: This is a monocentric cross-sectional study...
April 5, 2018: Public Health
https://www.readbyqxmd.com/read/29611014/cost-effectiveness-of-novel-treatment-of-hepatitis-c-virus-in-lebanese-patients
#6
Soumana C Nasser, Hanine Mansour, Tatiana Abi Nader, Mirna Metni
Background Limited data is available on Hepatitis C disease prevalence, treatment initiation and its cost-effectiveness in Lebanon and the whole Middle East. Objective The aim of the study is to assess whether initiation of novel Direct Acting Antiviral agents (DAAs) at early stage of hepatitis C is cost-effective in Lebanese patients. Setting Lebanon. Methods This modeling study was conducted from the perspective of Lebanese third party payers, where existing practice is based on international guidelines for the diagnosis and treatment of diseases...
April 2, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29607054/non-alcoholic-steatofibrosis-nasf-can-independently-predict-mortality-in-patients-with-non-alcoholic-fatty-liver-disease-nafld
#7
Pegah Golabi, Maria Stepanova, Huong T Pham, Rebecca Cable, Nila Rafiq, Haley Bush, Trevor Gogoll, Zobair M Younossi
Background: Hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) independently predicts mortality. Given liver biopsy's invasive nature, non-invasive method to assess hepatic steatosis and fibrosis provides NAFLD risk stratification algorithm in clinical practice. NAFLD fibrosis score (NFS) is simple and non-invasive predictive model recommended by American Association for the Study of Liver Disease (AASLD) Guideline to identify patients with NAFLD with fibrosis risk...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29596182/chapter-6-1-pediatric-chronic-hepatitis-b-and-c-30-years-of-espghan-clinical-research-and-recommendations
#8
Etienne M Sokal, Pilar Nannini
The expression of hepatitis B and C virus infections in children differs from that in adults and requires specific paediatric expertise. The European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) has been a pioneer in this field, having stressed the need for straightforward recommendations since the mid-1980s. Following much observation, surveillance, and research, a panel of ESPGHAN experts was able to develop such recommendations on hepatitis B infection in children in 2009, which was then followed in June 2013 by proper guidelines...
April 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29581103/data-generated-by-quantitative-lc-ms-proteomics-are-only-the-start-and-not-the-endpoint-optimization-of-qconcat-based-measurement-of-hepatic-udp-glucuronosyltransferase-enzymes-with-reference-to-catalytic-activity
#9
Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J Novak, Zubida M Al-Majdoub, Theunis C Goosen, Amin Rostami-Hodjegan, Jill Barber
Quantitative proteomic methods require optimization at several stages, including sample preparation, LC-MS/MS and data analysis, with the final analysis stage being less widely appreciated by end-users. Achour et al. (2017b) previously reported measurement of eight uridine-5'-diphospho-glucuronosyltransferases (UGT) generated by two laboratories [using stable isotope-labeled (SIL) peptides or quantitative concatemer (QconCAT)], which reflected significant disparity between proteomic methods. Initial analysis of QconCAT data showed lack of correlation with catalytic activity for several UGTs (1A4, 1A6, 1A9, 2B15) and moderate correlations for UGTs 1A1, 1A3 and 2B7 (Rs=0...
March 26, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29568202/differing-profiles-of-people-diagnosed-with-acute-and-chronic-hepatitis-b-virus-infection-in-british-columbia-canada
#10
Mawuena Binka, Zahid A Butt, Stanley Wong, Mei Chong, Jane A Buxton, Nuria Chapinal, Amanda Yu, Maria Alvarez, Maryam Darvishian, Jason Wong, Gina McGowan, Mikhail Torban, Mark Gilbert, Mark Tyndall, Mel Krajden, Naveed Z Janjua
AIM: To describe the characteristics of people diagnosed with acute and chronic hepatitis B virus (HBV) infection in British Columbia (BC). METHODS: We used data from the BC Hepatitis Testers Cohort (BC-HTC), which includes all individuals tested for hepatitis C virus (HCV) or human immunodeficiency virus (HIV) or those diagnosed with HBV or active tuberculosis in BC since 1990. These data were integrated with prescription drug, medical visit, hospitalization and mortality data...
March 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29566611/treatment-of-hcv-in-the-department-of-corrections-in-the-era-of-oral-medications
#11
Richard K Sterling, Reena Cherian, Shawn Lewis, Kathleen Genther, Carolyn Driscoll, Kelly Martin, Mary Beth Goode, Scott Matherly, Mohammad S Siddiqui, Velimir A Luketic, R Todd Stravitz, Puneet Puri, Hannah Lee, Paula Smith, Vaishali Patel, Arun J Sanyal
Chronic hepatitis C virus (HCV) is widely prevalent in the Virginia Department of Corrections (DOC). However, sustained virologic response (SVR) with all oral direct-acting antiviral (DAA) therapy is unknown. HCV treatment was provided through telemedicine following guidelines of the American Association for the Study of Liver Diseases and Infectious Diseases Society of America. SVR12 in the DOC was compared in two control groups: privately insured and indigent patients receiving care in HCV treatment clinics by the same providers during the same time period...
January 1, 2018: Journal of Correctional Health Care
https://www.readbyqxmd.com/read/29564364/risk-based-hepatitis-c-screening-in-pregnancy-is-less-reliable-than-universal-screening-a-retrospective-chart-review
#12
Sarah Boudova, Katrina Mark, Samer S El-Kamary
Current guidelines recommend only hepatitis C virus (HCV) risk-based screening during pregnancy. We examined screening practices at a major medical center and found inconsistent risk-based screening and the presence of HCV among women with no known risk factors. We make a case for the implementation of universal HCV screening during pregnancy.
March 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29561173/evaluation-of-statin-eligibility-prescribing-practices-and-therapeutic-responses-using-atp-iii-acc-aha-and-nla-dyslipidemia-treatment-guidelines-in-a-large-urban-cohort-of-hiv-infected-outpatients
#13
Matthew E Levy, Alan E Greenberg, Manya Magnus, Naji Younes, Amanda Castel
Statin coverage has been examined among HIV-infected patients using Adult Treatment Panel III (ATP III) and American College of Cardiology/American Heart Association (ACC/AHA) guidelines, although not with newer National Lipid Association (NLA) guidelines. We investigated statin eligibility, prescribing practices, and therapeutic responses using these three guidelines. Sociodemographic, clinical, and laboratory data were collected between 2011 and 2016 for HIV-infected outpatients enrolled in the DC Cohort, a multi-center, prospective, observational study in Washington, DC...
February 2018: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/29552922/-three-decades-of-the-hepatitis-c-virus-from-the-discovery-to-the-potential-global-elimination-the-success-of-translational-researches
#14
Alajos Pár, Gabriella Pár
More than 25 years after the discovery of hepatitis C virus, the development of the direct acting antivirals can lead to the regional or long-term global elimination of the virus with over 90% efficacy. This is the success of basic and clinical translational research. Yet, some unsolved challanges remain, such as the great number of unidentified patients who are not aware of their condition, the limited access to the therapy due to the high prices of the drugs, and the treatment of resistance-associated variants...
March 2018: Orvosi Hetilap
https://www.readbyqxmd.com/read/29551054/ezetimibe-decreased-nonalcoholic-fatty-liver-disease-activity-score-but-not-hepatic-steatosis
#15
Hyo Young Lee, Dae Won Jun, Hyun Jung Kim, Hyunwoo Oh, Waqar Khalid Saeed, Hyeongsik Ahn, Ramsey C Cheung, Mindie H Nguyen
Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by metaanalysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs)...
March 20, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29546809/hcv-viraemia-in-anti-hcv-negative-haemodialysis-patients-do-we-need-hcv-rna-detection-test
#16
Nikolaos Papadopoulos, Ioannis Griveas, Eirini Sveroni, Vasiliki Argiana, Antonios Kalliaropoulos, Beatriz Martinez-Gonzalez, Melanie Deutsch
BACKGROUND: Hepatitis C virus (HCV) infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. The KDIGO HCV guidelines of 2009 recommend that chronic haemodialysis patients be screened for HCV antibody upon admission to the dialysis clinic and every 6 months thereafter if susceptible to HCV infection. However, previous studies have shown the presence of HCV viraemia in anti-HCV-negative haemodialysis patients as up to 22%...
March 2018: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/29543988/hepatic-resection-compared-to-chemoembolization-in-intermediate-to-advanced-stage-hepatocellular-carcinoma-a-meta-analysis-of-high-quality-studies
#17
Myung Han Hyun, Young-Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
According to the American Association for the Study of Liver Disease treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) in patients with intermediate to advanced (BCLC stage-B/C) stage HCC to determine the current evidence. Through database search, we included 18 high-quality studies (1 randomized controlled trial [RCT], 5 propensity-score matching non-randomized comparative trials [NRCT], and 12 NRCTs) that compared survival outcomes of 5,986 patients after PH and TACE...
March 15, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29536563/systematic-review-with-meta-analysis-neuroimaging-in-hepatitis-c-chronic-infection
#18
REVIEW
G Oriolo, E Egmond, Z Mariño, M Cavero, R Navines, L Zamarrenho, R Solà, J Pujol, N Bargallo, X Forns, R Martin-Santos
BACKGROUND: Chronic hepatitis C is considered a systemic disease because of extra-hepatic manifestations. Neuroimaging has been employed in hepatitis C virus-infected patients to find in vivo evidence of central nervous system alterations. AIMS: Systematic review and meta-analysis of neuroimaging research in chronic hepatitis C treatment naive patients, or patients previously treated without sustained viral response, to study structural and functional brain impact of hepatitis C...
March 14, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29535247/moral-distress-with-obstacles-to-hepatitis-c-treatment-a-council-of-academic-family-medicine-educational-research-alliance-cera-study-of-family-medicine-program-directors
#19
Aditya Simha, Camille Maria Webb, Ramakrishna Prasad, N Randall Kolb, Peter J Veldkamp
BACKGROUND AND OBJECTIVE: To determine whether family medicine program directors (PDs) experienced moral distress due to obstacles to Hepatitis C virus (HCV) treatment, and to explore whether they found those obstacles to be unethical. DESIGN: An omnibus survey by the Council of Academic Family Medicine's Educational Research Alliance was administered to 452 and completed by 273 US-based PDs. The survey gauged attitudes and opinions regarding ethical dilemmas in patient access to HCV treatment...
March 2018: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/29535057/no-difference-in-effectiveness-of-8-vs-12-weeks-of-ledipasvir-and-sofosbuvir-for-treatment-of-hepatitis-c-in-black-patients
#20
Julia L Marcus, Leo B Hurley, Scott Chamberland, Jamila H Champsi, Laura C Gittleman, Daniel G Korn, Jennifer B Lai, Jennifer O Lam, Mary Patricia Pauly, Charles P Quesenberry, Joanna Ready, Varun Saxena, Suk Seo, David J Witt, Michael J Silverberg
BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week treatment course for black patients, but studies have not compared the effectiveness of 8 vs 12 weeks in black patients who are otherwise eligible for an 8-week treatment regimen. METHODS: We conducted an observational study of Kaiser Permanente Northern California members with HCV genotype 1 infection who were eligible for 8 weeks of treatment with ledipasvir and sofosbuvir (treatment-naïve, no cirrhosis, no HIV infection, level of HCV RNA <6 million IU/mL) and were treated for 8 or 12 weeks from October 2014 through December 2016...
March 10, 2018: Clinical Gastroenterology and Hepatology
keyword
keyword
64823
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"